Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD)? Pipeline Analysis Report 2025
Description
Systemic sclerosis (SS) in interstitial lung disease (ILD) is a serious condition that significantly impacts patient health, contributing to high morbidity and mortality rates. The prevalence of systemic sclerosis in interstitial lung disease varies widely, ranging from 25% to 95%, depending on the detection methods employed. Despite existing treatment options such as immunosuppressive therapies, there is a significant unmet clinical need for more effective treatments to slow disease progression. The increasing focus on precision medicine and targeted therapies is expected to drive advancements in the drug pipeline, offering hope for better management and improved patient outcomes in the coming years.
Report Coverage
The Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into systemic sclerosis (SS) in interstitial lung disease (ILD) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for systemic sclerosis (SS) in interstitial lung disease (ILD). The systemic sclerosis (SS) in interstitial lung disease (ILD) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with systemic sclerosis (SS) in interstitial lung disease (ILD) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to systemic sclerosis (SS) in interstitial lung disease (ILD).
Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline Outlook
Systemic sclerosis (SS) in interstitial lung disease (ILD) is a serious complication where inflammation and scarring (fibrosis) of lung tissue result in progressive loss of lung function. The condition arises when the body's immune system mistakenly attacks healthy lung tissue, causing the buildup of fibrous tissue that interferes with normal lung function. It can significantly impair the ability to breathe, contributing to morbidity and mortality.
Systemic sclerosis (SS) in interstitial lung disease (ILD) treatment typically includes immunosuppressive medications to manage inflammation, corticosteroids to reduce immune system activity, and antifibrotic agents to slow lung tissue scarring. In recent years, novel therapies targeting fibrosis and immune modulation have been actively researched, offering hope for improved outcomes and better management of disease progression.
Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) – Epidemiology
The prevalence of systemic sclerosis (SS) in interstitial lung disease (ILD) varies globally, ranging from 25% to 90%. Epidemiological studies highlight ethnic and regional differences, with African Americans and certain Asian populations showing a higher incidence. In comparison to Caucasians (38%), African Americans (54%) are diagnosed more commonly. Regional differences further highlight a higher prevalence in Central and Eastern Europe, as well as some parts of Asia.
Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of systemic sclerosis (SS) in interstitial lung disease (ILD) drug candidates based on several segmentations including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total systemic sclerosis (SS) in interstitial lung disease (ILD) clinical trials.
Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for systemic sclerosis (SS) in interstitial lung disease (ILD).
Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for systemic sclerosis (SS) in interstitial lung disease (ILD) report insights to include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for systemic sclerosis (SS) in interstitial lung disease (ILD). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of systemic sclerosis (SS) in interstitial lung disease (ILD) drug candidates.
Belimumab
A Phase 2/3 study, sponsored by GlaxoSmithKline, is investigating the efficacy and safety of belimumab in adults with systemic sclerosis-associated interstitial lung disease. The objective of this Phase 2/3 study is to evaluate belimumab's effect on lung function and extra-pulmonary manifestations. The study is expected to be completed by July 2027, with 300 participants enrolled.
Tulisokibart
The Phase 2 safety and efficacy study of Tulisokibart (MK-7240/PRA023) in subjects with systemic sclerosis-associated interstitial lung disease is being sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. This double-blind, randomized, placebo-controlled study aims to assess the safety and efficacy of Tulisokibart. The study is expected to be completed by June 2029, with an estimated 152 participants.
Reasons To Buy This Report
The Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for systemic sclerosis (SS) in interstitial lung disease (ILD). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline insights.
Key Questions Answered in the Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) – Pipeline Insight Report
Global Clinical Trials Market
Systemic Sclerosis Market
Report Coverage
The Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into systemic sclerosis (SS) in interstitial lung disease (ILD) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for systemic sclerosis (SS) in interstitial lung disease (ILD). The systemic sclerosis (SS) in interstitial lung disease (ILD) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with systemic sclerosis (SS) in interstitial lung disease (ILD) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to systemic sclerosis (SS) in interstitial lung disease (ILD).
Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline Outlook
Systemic sclerosis (SS) in interstitial lung disease (ILD) is a serious complication where inflammation and scarring (fibrosis) of lung tissue result in progressive loss of lung function. The condition arises when the body's immune system mistakenly attacks healthy lung tissue, causing the buildup of fibrous tissue that interferes with normal lung function. It can significantly impair the ability to breathe, contributing to morbidity and mortality.
Systemic sclerosis (SS) in interstitial lung disease (ILD) treatment typically includes immunosuppressive medications to manage inflammation, corticosteroids to reduce immune system activity, and antifibrotic agents to slow lung tissue scarring. In recent years, novel therapies targeting fibrosis and immune modulation have been actively researched, offering hope for improved outcomes and better management of disease progression.
Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) – Epidemiology
The prevalence of systemic sclerosis (SS) in interstitial lung disease (ILD) varies globally, ranging from 25% to 90%. Epidemiological studies highlight ethnic and regional differences, with African Americans and certain Asian populations showing a higher incidence. In comparison to Caucasians (38%), African Americans (54%) are diagnosed more commonly. Regional differences further highlight a higher prevalence in Central and Eastern Europe, as well as some parts of Asia.
Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of systemic sclerosis (SS) in interstitial lung disease (ILD) drug candidates based on several segmentations including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total systemic sclerosis (SS) in interstitial lung disease (ILD) clinical trials.
Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for systemic sclerosis (SS) in interstitial lung disease (ILD).
Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for systemic sclerosis (SS) in interstitial lung disease (ILD) report insights to include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) clinical trials:
- GlaxoSmithKline
- aTyr Pharma, Inc.
- Prometheus Biosciences, Inc.
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Genentech, Inc.
- Bristol-Myers Squibb
- Sanofi
- Boehringer Ingelheim
- ICON plc
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for systemic sclerosis (SS) in interstitial lung disease (ILD). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of systemic sclerosis (SS) in interstitial lung disease (ILD) drug candidates.
Belimumab
A Phase 2/3 study, sponsored by GlaxoSmithKline, is investigating the efficacy and safety of belimumab in adults with systemic sclerosis-associated interstitial lung disease. The objective of this Phase 2/3 study is to evaluate belimumab's effect on lung function and extra-pulmonary manifestations. The study is expected to be completed by July 2027, with 300 participants enrolled.
Tulisokibart
The Phase 2 safety and efficacy study of Tulisokibart (MK-7240/PRA023) in subjects with systemic sclerosis-associated interstitial lung disease is being sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. This double-blind, randomized, placebo-controlled study aims to assess the safety and efficacy of Tulisokibart. The study is expected to be completed by June 2029, with an estimated 152 participants.
Reasons To Buy This Report
The Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for systemic sclerosis (SS) in interstitial lung disease (ILD). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline insights.
Key Questions Answered in the Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) – Pipeline Insight Report
- Which companies/institutions are leading the systemic sclerosis (SS) in interstitial lung disease (ILD) drug development?
- What is the efficacy and safety profile of systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline drugs?
- Which company is leading the systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline development activities?
- What is the current systemic sclerosis (SS) in interstitial lung disease (ILD) commercial assessment?
- What are the opportunities and challenges present in the systemic sclerosis (SS) in interstitial lung disease (ILD) drug pipeline landscape?
- What is the efficacy and safety profile of systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline drugs?
- Which company is conducting major trials for systemic sclerosis (SS) in interstitial lung disease (ILD) drugs?
- Which companies/institutions are involved in systemic sclerosis (SS) in interstitial lung disease (ILD) collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in systemic sclerosis (SS) in interstitial lung disease (ILD)?
Global Clinical Trials Market
Systemic Sclerosis Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD)
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD)
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD): Epidemiology Snapshot
- 5.1 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Incidence by Key Markets
- 5.2 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) – Patients Seeking Treatment in Key Markets
- 6 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD): Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD): Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD), Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Belimumab
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: Tocilizumab|Drug: Nintedanib
- 10.2.3 Drug: Rituximab
- 10.2.4 Other Drugs
- 11 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: Tulisokibart
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: Mycophenolate Mofetil
- 11.2.3 Drug: efzofitimod 450 mg|Drug: efzofitimod 270 mg
- 11.2.4 Drug: Vixarelimab
- 11.2.5 Drug: Amlitelimab|Drug: BI 1015550
- 11.2.6 Other Drugs
- 12 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug 1
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD), Key Drug Pipeline Companies
- 14.1 GlaxoSmithKline
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 aTyr Pharma, Inc.
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Prometheus Biosciences, Inc.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Changchun GeneScience Pharmaceutical Co., Ltd.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Genentech, Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Bristol-Myers Squibb
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Sanofi
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Boehringer Ingelheim
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 ICON plc
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
